Search
for
Sort by
Research 17
- NDA Submission of Vepdegestrant (ARV-471) to U.S. FDA: The Beginning of a New Era of PROTAC Degraders
- Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
- Nanoliposomal Co-Delivery of AR-PROTAC and NFKBIZ siRNA for Synergistic Therapy of Androgenetic Alopecia
- Evolving CRBN ligands enhance the drug-like properties of protein degraders
- Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
- Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
- Fibrous scaffolds potentiate the paracrine function of mesenchymal stem cells: A new dimension in cell-material interaction
- Androgen receptor modulators: a review of recent patents and reports (2012-2018)
- Diagnosis and treatment of isolated autosomal recessive woolly hair/hypotrichosis
- PROTACs: A novel strategy for cancer drug discovery and development
- Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
- Emerging Strategies in Smart Nano-PROTAC for Stimuli-Responsive Protein Degradation and Precision Cancer Therapy
- Expanding the Scope of PROTACs: Opportunities and Challenges in Topical Delivery
- Peptide-Based PROTACs: Transitioning from Static Paradigm to a Dynamic Landscape within Targeted Protein Degradation
- Protein degradation: expanding the toolbox to restrain cancer drug resistance
- Advancing Design Strategy of PROTACs for Cancer Therapy
- Advancing PROTAC therapeutics through chemistry-guided design of smart delivery systems